Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Impact · against what's priced in

The FDA and CE Mark approvals for UltiSynq provide a modest growth catalyst for Abbott by expanding its CRM competitive footprint, though the price already assumes significant growth from other medical device drivers. The impact is limited as the market remains skeptical of the company's ability to sustain double-digit revenue growth.

ABT+0.15

Challenges what's priced in

The price assumes